Microgynon

Ethinylestradiol, the active ingredient in Microgynon, is a combined oral contraceptive presented as a 30 µg ethinylestradiol / 150 µg levonorgestrel tablet for oral use. It prevents pregnancy by inhibiting ovulation and altering cervical mucus and the endometrium in women of reproductive age. The product is indicated for reliable, reversible birth control in women who wish to avoid pregnancy.

GNH USA supplies Microgynon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Microgynon, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy.

- Contraception (prevention of pregnancy): provides reliable, reversible birth control for women of childbearing potential. - Regulation of menstrual cycles: helps establish predictable monthly bleeding patterns. - Treatment of moderate acne: reduces inflammatory lesions by modulating androgen activity.

Adverse reactions may occur with any hormonal contraceptive.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: discomfort or swelling of the breasts. - Spotting between periods: irregular light bleeding.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to the lungs. - Severe hypertension: markedly elevated blood pressure.

Use Microgynon only after medical assessment of risk factors.

- Smoking: avoid if over 35 years and a smoker due to increased thrombotic risk. - History of thromboembolism: contraindicated because of clotting potential. - Migraine with aura: avoid because of elevated stroke risk. - Liver disease: use with caution; hepatic impairment may alter hormone metabolism. - Drug interactions: review concomitant medications for possible efficacy reduction. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and heat.

Microgynon may interact with several medicines that affect hormone metabolism.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may reduce contraceptive efficacy. - Rifampin: decreases circulating hormone levels, increasing pregnancy risk. - St. John's wort: herbal inducer that can lower oral contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase hormone concentrations, raising side‑effect potential. - Macrolide antibiotics (e.g., erythromycin): can elevate plasma levels of ethinylestradiol. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may affect hormone metabolism and require monitoring.